Protein Aggregates in Ageing
Lead Research Organisation:
UNIVERSITY OF CAMBRIDGE
Department Name: Chemistry
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
People |
ORCID iD |
| David Klenerman (Primary Supervisor) |
Publications
De S
(2019)
Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression.
in Acta neuropathologica communications
Sideris D
(2021)
The Role of Neuroinflammation in Alzheimer's Disease
Studentship Projects
| Project Reference | Relationship | Related To | Start | End | Student Name |
|---|---|---|---|---|---|
| BB/P504816/1 | 31/03/2017 | 29/09/2021 | |||
| 2339512 | Studentship | BB/P504816/1 | 31/03/2017 | 30/08/2021 |
| Description | 1) Characterisation of size, structure, cell toxicity, and inflammatory potential of toxic protein aggregates found in the brain tissue of Alzheimer's disease patients. With a better characterisation of the proteins found in the brains of Alzheimer's patients, we can begin to understand the mechanisms underlying this disease, which will help contribute to the identification of new therapeutic targets. 2) Preclinical testing of AstraZeneca's antibodies for Alzheimer's disease-related proteins. This has given the company more information on the effectiveness and safety of their antibodies. More specific key findings cannot be mentioned here either due to confidentiality reasons, or not yet published. |
| Exploitation Route | 1) Assays used for the characterisation of the endogenous Alzheimer's disease brain proteins can be used to assess brain tissue from a larger cohort of Alzheimer's patients. Furthermore, the processing of these samples can be utilised by other research groups to further investigate these proteins. Lastly, our characterisations will hopefully contribute to an already growing amount of research, and help identify novel therapeutic targets. 2) AstraZeneca can see what worked or didn't work with their antibodies and reassess during the development of antibodies in the future. |
| Sectors | Healthcare Pharmaceuticals and Medical Biotechnology |